Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice

Saved in:
Bibliographic Details
Published inInflammatory bowel diseases Vol. 28; no. 2; pp. 318 - 321
Main Authors Alvarado, David M, Son, Juhee, Thackray, Larissa B, Gomez Castro, Maria Florencia, Prasad, Sarada, Cui, Xueyang, Sonnek, Naomi M, Diamond, Michael S, Ding, Siyuan, Ciorba, Matthew A
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.02.2022
Subjects
Angiotensin-Converting Enzyme 2 - drug effects
Angiotensin-Converting Enzyme 2 - metabolism
Animals
Brief Report - Basic Science
COVID-19
Intestines - drug effects
Intestines - metabolism
Mesalamine - pharmacology
Mice
SARS-CoV-2 - drug effects
Severity of Illness Index
COVID-19
mucosal immunology
intestine
5-ASA
Crohn’s disease
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These two authors contributed equally to this article.
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izab274